INmune Bio announced on October 21, 2026, that it had submitted its final pre-marketing authorization package for Ebstrocel to the UK Medicines and Healthcare products Regulatory Agency. The Ebstrocel filing, completed on October 20, precedes a planned full application in early February 2027 and potential UK approval in mid-2027, subject to regulatory review.
Key Takeaways
- The completed submission is a pre-application package, not a full marketing application or regulatory approval.
- INmune Bio says its revised UK strategy could bring potential approval forward by approximately six weeks.
- A planned US application in the second quarter of 2027 depends on feedback from an FDA meeting.
Table of Contents
- Ebstrocel filing changes the UK submission strategy
- US application preparation runs alongside the UK process
- Regulatory progress is not permission to sell
- Conclusion
Ebstrocel filing changes the UK submission strategy
INmune Bio’s revised UK regulatory timetable replaces a sequential rolling submission previously expected to begin in late 2026 with a complete marketing authorization application targeted for early February 2027. The company plans to finalize that application after receiving MHRA feedback on the pre-application package.
Management attributed the change to faster-than-expected manufacturing progress, including work on chemistry, manufacturing and controls. Submitting the complete package is intended to allow clinical, manufacturing and quality data to be assessed together.
The company believes the revised approach could shorten the path to potential approval by about six weeks. It anticipates an MHRA response within three to six months after submission, but that estimate remains subject to application validation, agency review and any requests for additional information.
| Item | Details |
|---|---|
| Therapy platform | Pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cells. |
| Target condition | Recessive dystrophic epidermolysis bullosa, abbreviated RDEB. |
| UK regulator | Medicines and Healthcare products Regulatory Agency. |
| US application | Biologics License Application, abbreviated BLA. |
US application preparation runs alongside the UK process
INmune Bio has engaged US regulatory advisers with rare-disease expertise to prepare and submit a Type B meeting request to the Food and Drug Administration. Subject to feedback from that meeting, it plans to file a Biologics License Application in the second quarter of 2027.
The company could seek traditional or accelerated approval, as appropriate. Chief Executive David Moss said INmune Bio is prioritizing its FDA application ahead of a European Medicines Agency submission, building on Ebstrocel’s US Orphan Drug and Rare Pediatric Disease designations.
Regulatory progress is not permission to sell
Ebstrocel, also identified as CORDStrom, is an investigational cell therapy targeting recessive dystrophic epidermolysis bullosa, a rare and severe genetic skin disorder. It has not received regulatory approval.
The announcement advances the company’s filing plans rather than establishing a commercial launch date. Both the UK approval window and the US filing target remain management expectations, with the timing dependent on regulatory feedback and review.
Conclusion
The next step is MHRA feedback on the submitted pre-application package, followed by INmune Bio’s targeted full UK application in early February 2027. Potential approval in mid-2027 remains conditional, not an agency commitment.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
